Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male and Female Subjects.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
GW842166X is a selective non-cannabinoid CB2 receptor agonist, which is undergoing clinical development as a novel oral treatment for inflammatory pain. The purpose of the study is to compare the effects of formulation, food and particle size on the pharmacokinetic profiles of a single 175mg dose of GW842166X in healthy male and female volunteers.
Epistemonikos ID: eede605b03e5571ae0a55102b3dc07c749162323
First added on: May 04, 2024